Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma

被引:60
作者
Guruswamy, S
Lighfoot, S
Gold, MA
Hassan, R
Berlin, KD
Ivey, RT
Benbrook, DM
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73190 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73190 USA
[5] Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2001年 / 93卷 / 07期
关键词
D O I
10.1093/jnci/93.7.516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Retinoic acid analogues, called retinoids, have shown promise in clinical trials in preventing breast and ovarian cancers. Classic retinoids bind to retinoic acid receptors, which regulate cell growth. Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials. At lower concentrations (less than or equal to1 muM), 4-HPR acts like classic retinoids, by inducing differentiation through a receptor-dependent mechanism. Our goal was to compare the effects of novel receptor-independent (apoptotic) retinoids with those of classic growth-inhibitory retinoids at clinically achievable doses on growth, differentiation, and apoptosis in ovarian tissue. Methods: Four receptor-independent (apoptotic) and seven growth-inhibitory retinoids, including synthetic, low-toxicity compounds called heteroarotinoids, were administered at concentrations of 1 muM to organotypic cultures of ovarian primary and cancer cell lines: OVCAR-3, Caov-3, and SK-OV-3. After fixation, embedding, and sectioning, the growth fraction was quantified by measuring expression of the proliferation marker Ki-67/myb, differentiation was assessed by expression of mucin, and apoptosis was evaluated by the TUNEL assay. Spearman correlation analysis was performed on the data, and all P values were two-sided. Results: All 11 retinoids reversed characteristics associated with the cancerous phenotype in all neoplastic cultures. Glandular structures were observed consistently in retinoid-treated, but not in untreated, OVCAR-3 and Caov-3 cultures. All retinoids decreased growth fractions, and some increased mucin expression. All receptor-independent retinoids and two receptor-dependent retinoids induced apoptosis, and the induction correlated significantly with increased expression of the mucin MUC1 (r =.83; P =.03), Retinoids with ester-linking groups did not induce apoptosis but decreased the growth fraction in correlation with MUC1 induction (r = -.93; P =.02). Conclusions: At clinically achievable concentrations, all retinoids tested decrease the growth fraction, induce differentiation and apoptosis, Induction of MUC1 expression is implicated in the mechanisms of action.
引用
收藏
页码:516 / 525
页数:10
相关论文
共 56 条
[1]  
Aebi S, 1997, CLIN CANCER RES, V3, P2033
[2]  
Alberts DS, 1999, CANCER RES, V59, P4743
[3]   A NOVEL ORPHAN RECEPTOR-SPECIFIC FOR A SUBSET OF THYROID HORMONE-RESPONSIVE ELEMENTS AND ITS INTERACTION WITH THE RETINOID/THYROID HORMONE-RECEPTOR SUBFAMILY [J].
APFEL, R ;
BENBROOK, D ;
LERNHARDT, E ;
ORTIZ, MA ;
SALBERT, G ;
PFAHL, M .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (10) :7025-7035
[4]   MORPHOMETRIC DATA TO FIGO STAGE AND HISTOLOGICAL TYPE AND GRADE FOR PROGNOSIS OF OVARIAN-TUMORS [J].
BAAK, JPA ;
WISSEBREKELMANS, ECM ;
LANGLEY, FA ;
TALERMAN, A ;
DELEMARRE, JFM .
JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (12) :1340-1346
[5]   Making the most of mucin: A novel target for tumor immunotherapy [J].
BarrattBoyes, SM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (03) :142-151
[6]   Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships [J].
Benbrook, DM ;
Subramanian, S ;
Gale, JB ;
Liu, SQ ;
Brown, CW ;
Boehm, MF ;
Berlin, KD .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) :3753-3757
[7]   Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity [J].
Benbrook, DM ;
Madler, MM ;
Spruce, LW ;
Birckbichler, PJ ;
Nelson, EC ;
Subramanian, S ;
Weerasekare, GM ;
Gale, JB ;
Patterson, MK ;
Wang, BH ;
Wang, W ;
Lu, SN ;
Rowland, TC ;
DiSivestro, P ;
Lindamood, C ;
Hill, DL ;
Berlin, KD .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (22) :3567-3583
[8]  
BERLIN KD, 2001, HETEROAROTINOIDS CON
[9]   Hereditary ovarian cancer: Molecular genetics and clinical implications [J].
Boyd, J ;
Rubin, SC .
GYNECOLOGIC ONCOLOGY, 1997, 64 (02) :196-206
[10]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003